HighGravityDataInsulet — Nov 7, 2024 release
Fiscal 2024 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001145197-24-000043
Showing in the filing
Operating margin
“approximately 14.5%”
Period
FY2024
Measure
GAAP-tied
Source
Prose
All guidance in this release · 19
Total Omnipod revenue growth (constant curre… for FY2024
“21% to 22%”
U.S. Omnipod revenue growth (constant curren… for FY2024
“19% to 21%”
International Omnipod revenue growth (consta… for FY2024
“25% to 27%”
Drug Delivery revenue growth (constant curre… for FY2024
“(10)% to (5)%”
Total revenue growth for FY2024
“12% to 15%”
Total Omnipod revenue growth for FY2024
“13% to 16%”
Total Omnipod revenue growth (constant curre… for Q4 FY2024
“13% to 16%”
U.S. Omnipod revenue growth for FY2024
“9% to 12%”
U.S. Omnipod revenue growth (constant curren… for Q4 FY2024
“9% to 12%”
International Omnipod revenue growth for FY2024
“30% to 33%”
International Omnipod revenue growth (consta… for Q4 FY2024
“30% to 33%”
Drug Delivery revenue growth for FY2024
“(20)% to (15)% (approximately $7 million to $8 million)”
Drug Delivery revenue growth (constant curre… for Q4 FY2024
“(20)% to (15)% (approximately $7 million to $8 million)”
Gross margin for FY2024
“approximately 69%”
Operating margin for FY2024
“approximately 14.5%”
International Omnipod Revenue Growth (GAAP) for FY2024
“26% - 28%”
Total Revenue Growth (Constant Currency) for FY2024
“20% - 21%”
International Omnipod Revenue Growth (GAAP) for Q4 FY2024
“31% - 34%”
Total Revenue Growth (Constant Currency) for Q4 FY2024
“12% - 15%”
Exhibit 99.1 · the passage around this item
… earlier in the release
Omnipod of 9% to 12% 5 ▪ International Omnipod of 30% to 33% ◦ Drug Delivery of (20)% to (15)% (app roximately $7 million to $8 million) Gross Margin and Operating Margin Guidance: For the year ending December 31, 2024 , the Company now expects gross margin to be approximately 69% (previously 68% to 69%, closer to the high end). For the year ending December 31, 2024, the Company is raising its expected operating margin by 50 basis points to approximately 14.5% . Conference Call: Insulet will host a conference call at 4:30 p.m. (Eastern Time) on November 7, 2024 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com, “Events and Presentations,” and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod 3 Omnipod was the most frequently chosen pum p in the past year among people new to an insulin pump in a survey conducted by dQ&A across Germany, Italy, France, United Kingdom, Spain, Netherlands, Sweden. N=3646; 1H'24: P.47 (August 2024). 4 Renard E et al. Diabetes Care.2024; 47(12):1-10. https://doi.org/10.2337/dc24-1550. Results are from Insulet’s first international randomized controlled trial of Omnipod 5 and demonstrated a 17.5% increase in time in range in those
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.